Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 2Phase 1 2

Status

Recruiting 5Active not recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5CNS 1

Conditions

Melanoma 3Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Opdualag × Clear all
NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Stanford University

Phase 2 Recruiting
60 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT06295159 2026-04-01

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
90 enrolled
Dermatologic

Melanoma

NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Melanoma Institute Australia

Phase 2 Recruiting
20 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT06624475 2026-02-05

NEON

University of California, San Diego

Phase 2 Recruiting
30 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT06319196 2025-12-03

ClearMe

University Health Network, Toronto

Phase 2 Recruiting
54 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡